Comparison of Vision and Development Outcomes in Laser- and Bevacizumab-Treated Infants With Retinopathy of Prematurity
Phase of Trial: Phase III/IV
Latest Information Update: 07 Jan 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 28 Feb 2017 Planned number of patients changed from 100 to 150.
- 10 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 03 Dec 2013 New trial record